EC Number   |
Application |
Reference |
|---|
   3.5.1.98 | drug development |
the enzyme might be a promising target for the development of novel anti-babesial drugs |
735331 |
| 3.5.1.98 | medicine |
1,2,4-oxadiazole-containing hydroxamic acid derivatives are discovered as histone deacetylase inhibitors for potential application in cancer therapy |
756656 |
| 3.5.1.98 | medicine |
a representative compound, (2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(2-pyrrolidin-1-ylethyl)-1H-benzimidazol-5-yl]prop-2-enamide, SB639, has demonstrated antitumor activity in a colon cancer xenograft model |
696662 |
| 3.5.1.98 | medicine |
application of HDAC inhibitors in cancer cell lines and mouse model systems leads to interruption of the cell cycle, differentiation and apoptosis, clinical studies have shown tumor repression and improvement of patient symptoms without significant side effects |
699231 |
| 3.5.1.98 | medicine |
because of their fundamental role in gene expression, histone deacetylase proteins are promising targets for cancer treatment |
699443 |
| 3.5.1.98 | medicine |
class I and II HDACs are generally considered valuable therapeutic targets for the treatment of leukemia and solid tumors |
696616 |
| 3.5.1.98 | medicine |
compared with healthy non-smokers, HDAC activity in the peripheral blood mononuclear cells of patients with chronic obstructive pulmonary disease is decreased by 40%. In patients with chronic obstructive pulmonary disease, HDAC activity is negatively correlated to smoke intensity. In chronic obstructive pulmonary disease patients who have smoked for more than 40 pack-years, HDAC activity in peripheral blood mononuclear cells is 40% lower than that in chronic obstructive pulmonary disease patients who have smoked fewer than 40 pack-years. Serum CXCL8 levels in patients with chronic obstructive pulmonary disease are significantly higher than that in controls and are negatively correlated to HDAC activities |
720163 |
| 3.5.1.98 | medicine |
general inhibition of histone deacetylases alters the balance of T helper 1 and T helper 2 effector cell activation and migration |
678911 |
| 3.5.1.98 | medicine |
HDAC inhibition is a clinically validated therapeutic strategy for cancer treatment |
696716 |
| 3.5.1.98 | medicine |
HDAC inhibitors are a promising class of anticancer agents |
696610 |
